[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBkSh8_7EXn_AY4EPJ4wGOV-4yyT4Ge7uXuW0iDEDIyA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":73,"rows":80},"All India Institute of Medical Sciences, Bhubaneswar",[4],53,false,14,2,4071,12,13,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Schizophrenia",5,{"name":18,"count":19},"Treatment Resistant Schizophrenia",3,{"name":21,"count":9},"Major Depressive Disorder",{"name":23,"count":9},"Oral Lichen Planus",{"name":25,"count":9},"Morbid Obesity",{"name":27,"count":9},"Hypothyroidism",{"name":29,"count":9},"Non-Alcoholic Fatty Liver Disease",{"name":31,"count":9},"Perforated Bowel",[33,38,43,48,53,58,63,68],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06505668","Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.","2025-06-30","Atenolol 25 mg",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06501339","Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia","2025-10-31","Aripiprazole",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07145034","Evaluation Of Efficacy And Safety Of Prosman™ (Prunus Domestica Extract) On Prostate Function, Serum Testosterone Levels And Quality Of Life","2026-05-30","Prosman",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06803485","Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder","2026-08","Venlafaxine",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT07143474","Effect of RhizomK on Testosterone Levels, the Anabolic Response to Exercise and Overall Quality of Life in Physically Active Healthy Males","2026-10","RhizomK",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07131813","Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus","2027-01-01","Tofacitinib 5 mg BID and Triamcinolone ointment",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07454772","Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis","2027-04-04","Steroid",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07504250","Hyaluronic Acid vs Mitomycin-C in External Dacryocystorhinostomy","2027-10-30","Hyaluronic Acid",[74,75,76,77,78,79],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[81,118,139,162,180,215,237,260,278,299,322,340,362,396,427,464,486,523,547,573,591,609,634,662,680,698,724,742,767,785,809,827,845,863,881,904,922,949,974,992,1010,1036,1054,1077,1103,1128,1146,1174,1192,1217,1241,1270,1297,1323,1347,1376,1394,1420],{"intervention":42,"totalTrials":9,"cells":82},{"EARLY_PHASE1":83,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":116},{"trials":84,"activeCount":85},[],0,{"trials":87,"activeCount":85},[],{"trials":89,"activeCount":85},[],{"trials":91,"activeCount":85},[],{"trials":93,"activeCount":115,"soonestReadout":41},[94,106],{"nctId":95,"briefTitle":96,"status":97,"phases":98,"primaryCompletion":99,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":104},"NCT06236451","Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia","COMPLETED",[78],"2025-11-03","2025-11-12","2024-04-05",60,[15],[42,105],"Risperidone",{"nctId":39,"briefTitle":40,"status":107,"phases":108,"primaryCompletion":41,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NOT_YET_RECRUITING",[78],"2026-03-31","2024-08-10",40,[113],"Clozapine Resistant Schizophrenia",[42],1,{"trials":117,"activeCount":85},[],{"intervention":62,"totalTrials":115,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":137},{"trials":121,"activeCount":85},[],{"trials":123,"activeCount":85},[],{"trials":125,"activeCount":85},[],{"trials":127,"activeCount":85},[],{"trials":129,"activeCount":115,"soonestReadout":61},[130],{"nctId":59,"briefTitle":60,"status":131,"phases":132,"primaryCompletion":61,"completion":133,"start":134,"enrollment":102,"conditions":135,"interventions":136},"RECRUITING",[78],"2027-06-01","2025-10-10",[23],[62],{"trials":138,"activeCount":85},[],{"intervention":72,"totalTrials":115,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":160},{"trials":142,"activeCount":85},[],{"trials":144,"activeCount":85},[],{"trials":146,"activeCount":85},[],{"trials":148,"activeCount":85},[],{"trials":150,"activeCount":115,"soonestReadout":71},[151],{"nctId":69,"briefTitle":70,"status":107,"phases":152,"primaryCompletion":71,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":158},[78],"2027-12-31","2026-04-01",36,[157],"Dacryocystitis",[72,159],"Mitomycin -C",{"trials":161,"activeCount":85},[],{"intervention":159,"totalTrials":115,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":178},{"trials":165,"activeCount":85},[],{"trials":167,"activeCount":85},[],{"trials":169,"activeCount":85},[],{"trials":171,"activeCount":85},[],{"trials":173,"activeCount":115,"soonestReadout":71},[174],{"nctId":69,"briefTitle":70,"status":107,"phases":175,"primaryCompletion":71,"completion":153,"start":154,"enrollment":155,"conditions":176,"interventions":177},[78],[157],[72,159],{"trials":179,"activeCount":85},[],{"intervention":52,"totalTrials":9,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":201},{"trials":183,"activeCount":85},[],{"trials":185,"activeCount":85},[],{"trials":187,"activeCount":85},[],{"trials":189,"activeCount":85},[],{"trials":191,"activeCount":115,"soonestReadout":51},[192],{"nctId":49,"briefTitle":50,"status":131,"phases":193,"primaryCompletion":51,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},[78],"2026-11","2025-03-11",84,[198],"Somatic Symptom Disorder (DSM-V)",[52,200],"Dosulepin",{"trials":202,"activeCount":85},[203],{"nctId":204,"briefTitle":205,"status":97,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT03126188","Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression",[],"2017-12-31","2018-02-28","2017-04-05",105,[212],"Depressive Episode",[214,200,52],"Sertraline",{"intervention":200,"totalTrials":9,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":85},[],{"trials":220,"activeCount":85},[],{"trials":222,"activeCount":85},[],{"trials":224,"activeCount":85},[],{"trials":226,"activeCount":115,"soonestReadout":51},[227],{"nctId":49,"briefTitle":50,"status":131,"phases":228,"primaryCompletion":51,"completion":194,"start":195,"enrollment":196,"conditions":229,"interventions":230},[78],[198],[52,200],{"trials":232,"activeCount":85},[233],{"nctId":204,"briefTitle":205,"status":97,"phases":234,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":235,"interventions":236},[],[212],[214,200,52],{"intervention":67,"totalTrials":115,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":254,"PHASE4":256,"NA":258},{"trials":240,"activeCount":85},[],{"trials":242,"activeCount":85},[],{"trials":244,"activeCount":115,"soonestReadout":66},[245],{"nctId":64,"briefTitle":65,"status":107,"phases":246,"primaryCompletion":66,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":252},[75,76],"2027-07-04","2026-03-15",72,[251],"Granulomatous Mastitis",[67,253],"Antibiotic",{"trials":255,"activeCount":85},[],{"trials":257,"activeCount":85},[],{"trials":259,"activeCount":85},[],{"intervention":253,"totalTrials":115,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":263,"activeCount":85},[],{"trials":265,"activeCount":85},[],{"trials":267,"activeCount":115,"soonestReadout":66},[268],{"nctId":64,"briefTitle":65,"status":107,"phases":269,"primaryCompletion":66,"completion":247,"start":248,"enrollment":249,"conditions":270,"interventions":271},[75,76],[251],[67,253],{"trials":273,"activeCount":85},[],{"trials":275,"activeCount":85},[],{"trials":277,"activeCount":85},[],{"intervention":57,"totalTrials":115,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":286,"PHASE4":288,"NA":290},{"trials":281,"activeCount":85},[],{"trials":283,"activeCount":85},[],{"trials":285,"activeCount":85},[],{"trials":287,"activeCount":85},[],{"trials":289,"activeCount":85},[],{"trials":291,"activeCount":115,"soonestReadout":56},[292],{"nctId":54,"briefTitle":55,"status":107,"phases":293,"primaryCompletion":56,"completion":294,"start":295,"enrollment":102,"conditions":296,"interventions":298},[79],"2027-02","2025-10",[297],"Adult Healthy Volunteers",[57],{"intervention":37,"totalTrials":115,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":302,"activeCount":85},[],{"trials":304,"activeCount":85},[],{"trials":306,"activeCount":85},[],{"trials":308,"activeCount":85},[],{"trials":310,"activeCount":85},[],{"trials":312,"activeCount":115,"soonestReadout":36},[313],{"nctId":34,"briefTitle":35,"status":131,"phases":314,"primaryCompletion":36,"completion":36,"start":315,"enrollment":111,"conditions":316,"interventions":320},[79],"2023-08-01",[18,317,318,319],"Clozapine Adverse Reaction","Heart Rate Variability","Tachycardia",[37,321],"Ivabradine 10mg",{"intervention":321,"totalTrials":115,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":85},[],{"trials":327,"activeCount":85},[],{"trials":329,"activeCount":85},[],{"trials":331,"activeCount":85},[],{"trials":333,"activeCount":85},[],{"trials":335,"activeCount":115,"soonestReadout":36},[336],{"nctId":34,"briefTitle":35,"status":131,"phases":337,"primaryCompletion":36,"completion":36,"start":315,"enrollment":111,"conditions":338,"interventions":339},[79],[18,317,318,319],[37,321],{"intervention":47,"totalTrials":115,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":343,"activeCount":85},[],{"trials":345,"activeCount":85},[],{"trials":347,"activeCount":85},[],{"trials":349,"activeCount":85},[],{"trials":351,"activeCount":85},[],{"trials":353,"activeCount":115,"soonestReadout":46},[354],{"nctId":44,"briefTitle":45,"status":107,"phases":355,"primaryCompletion":46,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},[79],"2026-09-30","2025-09-07",38,[360],"Healthy",[47],{"intervention":363,"totalTrials":9,"cells":364},"Dextromethorphan",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":394},{"trials":366,"activeCount":85},[],{"trials":368,"activeCount":85},[],{"trials":370,"activeCount":85},[],{"trials":372,"activeCount":85},[],{"trials":374,"activeCount":85},[375,385],{"nctId":376,"briefTitle":377,"status":97,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":102,"conditions":382,"interventions":383},"NCT05181527","Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder",[78],"2023-09-30","2023-11-30","2022-02-10",[21],[384,363],"Selective Serotonin Reuptake Inhibitors",{"nctId":386,"briefTitle":387,"status":97,"phases":388,"primaryCompletion":389,"completion":390,"start":391,"enrollment":111,"conditions":392,"interventions":393},"NCT05944510","Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia",[78],"2024-10-15","2025-04-30","2023-08-31",[18],[363],{"trials":395,"activeCount":85},[],{"intervention":105,"totalTrials":9,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":425},{"trials":399,"activeCount":85},[],{"trials":401,"activeCount":85},[],{"trials":403,"activeCount":85},[],{"trials":405,"activeCount":85},[],{"trials":407,"activeCount":85},[408,421],{"nctId":409,"briefTitle":410,"status":97,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":417},"NCT03075657","Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia",[78],"2018-06-15","2018-08-31","2017-05-01",120,[15],[105,418,419,420],"Risperidone and Ramelteon","Haloperidol","Haloperidol and Ramelteon",{"nctId":95,"briefTitle":96,"status":97,"phases":422,"primaryCompletion":99,"completion":100,"start":101,"enrollment":102,"conditions":423,"interventions":424},[78],[15],[42,105],{"trials":426,"activeCount":85},[],{"intervention":428,"totalTrials":9,"cells":429},"Prednisolone",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":462},{"trials":431,"activeCount":85},[],{"trials":433,"activeCount":85},[],{"trials":435,"activeCount":85},[],{"trials":437,"activeCount":85},[],{"trials":439,"activeCount":85},[440,452],{"nctId":441,"briefTitle":442,"status":97,"phases":443,"primaryCompletion":444,"completion":445,"start":315,"enrollment":446,"conditions":447,"interventions":449},"NCT05984381","Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid",[78],"2025-01-03","2025-04-01",62,[448],"Bullous Pemphigoid",[428,450,451],"Dapsone","Methotrexate",{"nctId":453,"briefTitle":454,"status":97,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT06260904","Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus",[78],"2025-10-30","2024-01-26",64,[23],[428,461,451],"Apremilast",{"trials":463,"activeCount":85},[],{"intervention":451,"totalTrials":9,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":484},{"trials":467,"activeCount":85},[],{"trials":469,"activeCount":85},[],{"trials":471,"activeCount":85},[],{"trials":473,"activeCount":85},[],{"trials":475,"activeCount":85},[476,480],{"nctId":441,"briefTitle":442,"status":97,"phases":477,"primaryCompletion":444,"completion":445,"start":315,"enrollment":446,"conditions":478,"interventions":479},[78],[448],[428,450,451],{"nctId":453,"briefTitle":454,"status":97,"phases":481,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":482,"interventions":483},[78],[23],[428,461,451],{"trials":485,"activeCount":85},[],{"intervention":487,"totalTrials":9,"cells":488},"Oxcarbazepine",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":521},{"trials":490,"activeCount":85},[],{"trials":492,"activeCount":85},[],{"trials":494,"activeCount":85},[],{"trials":496,"activeCount":85},[],{"trials":498,"activeCount":85},[499,509],{"nctId":500,"briefTitle":501,"status":97,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":508},"NCT02456896","Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder",[78],"2015-12","2015-06",50,[507],"Bipolar Disorder",[487],{"nctId":510,"briefTitle":511,"status":97,"phases":512,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT02705768","Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures",[78],"2017-02","2017-03","2016-04",90,[518],"Seizures, Focal",[520,487],"Carbamazepine",{"trials":522,"activeCount":85},[],{"intervention":524,"totalTrials":115,"cells":525},"Clozapine",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":534,"NA":545},{"trials":527,"activeCount":85},[],{"trials":529,"activeCount":85},[],{"trials":531,"activeCount":85},[],{"trials":533,"activeCount":85},[],{"trials":535,"activeCount":85},[536],{"nctId":537,"briefTitle":538,"status":97,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":102,"conditions":543,"interventions":544},"NCT03807882","Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia",[78],"2020-05-31","2020-06-30","2019-02-01",[18],[524],{"trials":546,"activeCount":85},[],{"intervention":548,"totalTrials":115,"cells":549},"Lithium Carbonate",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":571},{"trials":551,"activeCount":85},[],{"trials":553,"activeCount":85},[],{"trials":555,"activeCount":85},[],{"trials":557,"activeCount":85},[],{"trials":559,"activeCount":85},[560],{"nctId":561,"briefTitle":562,"status":97,"phases":563,"primaryCompletion":564,"completion":565,"start":566,"enrollment":102,"conditions":567,"interventions":569},"NCT04222816","Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder",[78],"2021-12-31","2022-01-07","2020-01-16",[568],"Bipolar Affective Disorder",[548,570],"Sodium chloride",{"trials":572,"activeCount":85},[],{"intervention":570,"totalTrials":115,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":589},{"trials":576,"activeCount":85},[],{"trials":578,"activeCount":85},[],{"trials":580,"activeCount":85},[],{"trials":582,"activeCount":85},[],{"trials":584,"activeCount":85},[585],{"nctId":561,"briefTitle":562,"status":97,"phases":586,"primaryCompletion":564,"completion":565,"start":566,"enrollment":102,"conditions":587,"interventions":588},[78],[568],[548,570],{"trials":590,"activeCount":85},[],{"intervention":384,"totalTrials":115,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":607},{"trials":594,"activeCount":85},[],{"trials":596,"activeCount":85},[],{"trials":598,"activeCount":85},[],{"trials":600,"activeCount":85},[],{"trials":602,"activeCount":85},[603],{"nctId":376,"briefTitle":377,"status":97,"phases":604,"primaryCompletion":379,"completion":380,"start":381,"enrollment":102,"conditions":605,"interventions":606},[78],[21],[384,363],{"trials":608,"activeCount":85},[],{"intervention":610,"totalTrials":115,"cells":611},"Atorvastatin 10mg",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":632},{"trials":613,"activeCount":85},[],{"trials":615,"activeCount":85},[],{"trials":617,"activeCount":85},[],{"trials":619,"activeCount":85},[],{"trials":621,"activeCount":85},[622],{"nctId":623,"briefTitle":624,"status":97,"phases":625,"primaryCompletion":626,"completion":564,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT03906539","Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia",[78],"2021-11-30","2019-05-22",150,[630],"Dyslipidemias",[610],{"trials":633,"activeCount":85},[],{"intervention":635,"totalTrials":115,"cells":636},"Quetiapine",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":660},{"trials":638,"activeCount":85},[],{"trials":640,"activeCount":85},[],{"trials":642,"activeCount":85},[],{"trials":644,"activeCount":85},[],{"trials":646,"activeCount":85},[647],{"nctId":648,"briefTitle":649,"status":650,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":628,"conditions":655,"interventions":657},"NCT04936126","Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression","UNKNOWN",[78],"2024-07-07","2024-09-07","2021-08-07",[656],"Treatment Resistant Depression",[635,658,659],"Amantadine","Pramipexole",{"trials":661,"activeCount":85},[],{"intervention":658,"totalTrials":115,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":678},{"trials":665,"activeCount":85},[],{"trials":667,"activeCount":85},[],{"trials":669,"activeCount":85},[],{"trials":671,"activeCount":85},[],{"trials":673,"activeCount":85},[674],{"nctId":648,"briefTitle":649,"status":650,"phases":675,"primaryCompletion":652,"completion":653,"start":654,"enrollment":628,"conditions":676,"interventions":677},[78],[656],[635,658,659],{"trials":679,"activeCount":85},[],{"intervention":659,"totalTrials":115,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":696},{"trials":683,"activeCount":85},[],{"trials":685,"activeCount":85},[],{"trials":687,"activeCount":85},[],{"trials":689,"activeCount":85},[],{"trials":691,"activeCount":85},[692],{"nctId":648,"briefTitle":649,"status":650,"phases":693,"primaryCompletion":652,"completion":653,"start":654,"enrollment":628,"conditions":694,"interventions":695},[78],[656],[635,658,659],{"trials":697,"activeCount":85},[],{"intervention":699,"totalTrials":115,"cells":700},"Flunarizine 5mg",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":722},{"trials":702,"activeCount":85},[],{"trials":704,"activeCount":85},[],{"trials":706,"activeCount":85},[],{"trials":708,"activeCount":85},[],{"trials":710,"activeCount":85},[711],{"nctId":712,"briefTitle":713,"status":97,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":102,"conditions":718,"interventions":720},"NCT04064814","Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population",[78],"2021-04-30","2021-06-30","2019-09-14",[719],"Adolescent Migraine",[699,721],"Alpha lipoic acid 300mg",{"trials":723,"activeCount":85},[],{"intervention":721,"totalTrials":115,"cells":725},{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":730,"PHASE3":732,"PHASE4":734,"NA":740},{"trials":727,"activeCount":85},[],{"trials":729,"activeCount":85},[],{"trials":731,"activeCount":85},[],{"trials":733,"activeCount":85},[],{"trials":735,"activeCount":85},[736],{"nctId":712,"briefTitle":713,"status":97,"phases":737,"primaryCompletion":715,"completion":716,"start":717,"enrollment":102,"conditions":738,"interventions":739},[78],[719],[699,721],{"trials":741,"activeCount":85},[],{"intervention":743,"totalTrials":115,"cells":744},"Amisulpride",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":765},{"trials":746,"activeCount":85},[],{"trials":748,"activeCount":85},[],{"trials":750,"activeCount":85},[],{"trials":752,"activeCount":85},[],{"trials":754,"activeCount":85},[755],{"nctId":756,"briefTitle":757,"status":97,"phases":758,"primaryCompletion":759,"completion":716,"start":760,"enrollment":102,"conditions":761,"interventions":763},"NCT04876521","Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression",[78],"2021-06-09","2019-10-14",[762],"Post-Schizophrenic Depression",[743,764],"Olanzapine-Fluoxetine Combination",{"trials":766,"activeCount":85},[],{"intervention":764,"totalTrials":115,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":783},{"trials":770,"activeCount":85},[],{"trials":772,"activeCount":85},[],{"trials":774,"activeCount":85},[],{"trials":776,"activeCount":85},[],{"trials":778,"activeCount":85},[779],{"nctId":756,"briefTitle":757,"status":97,"phases":780,"primaryCompletion":759,"completion":716,"start":760,"enrollment":102,"conditions":781,"interventions":782},[78],[762],[743,764],{"trials":784,"activeCount":85},[],{"intervention":786,"totalTrials":115,"cells":787},"Aripiprazole 10 MG",{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":807},{"trials":789,"activeCount":85},[],{"trials":791,"activeCount":85},[],{"trials":793,"activeCount":85},[],{"trials":795,"activeCount":85},[],{"trials":797,"activeCount":85},[798],{"nctId":799,"briefTitle":800,"status":650,"phases":801,"primaryCompletion":380,"completion":802,"start":803,"enrollment":102,"conditions":804,"interventions":806},"NCT05766540","Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT",[78],"2023-12-31","2023-08-20",[805],"Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia",[786],{"trials":808,"activeCount":85},[],{"intervention":418,"totalTrials":115,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":825},{"trials":812,"activeCount":85},[],{"trials":814,"activeCount":85},[],{"trials":816,"activeCount":85},[],{"trials":818,"activeCount":85},[],{"trials":820,"activeCount":85},[821],{"nctId":409,"briefTitle":410,"status":97,"phases":822,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":823,"interventions":824},[78],[15],[105,418,419,420],{"trials":826,"activeCount":85},[],{"intervention":419,"totalTrials":115,"cells":828},{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":843},{"trials":830,"activeCount":85},[],{"trials":832,"activeCount":85},[],{"trials":834,"activeCount":85},[],{"trials":836,"activeCount":85},[],{"trials":838,"activeCount":85},[839],{"nctId":409,"briefTitle":410,"status":97,"phases":840,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":841,"interventions":842},[78],[15],[105,418,419,420],{"trials":844,"activeCount":85},[],{"intervention":420,"totalTrials":115,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":855,"NA":861},{"trials":848,"activeCount":85},[],{"trials":850,"activeCount":85},[],{"trials":852,"activeCount":85},[],{"trials":854,"activeCount":85},[],{"trials":856,"activeCount":85},[857],{"nctId":409,"briefTitle":410,"status":97,"phases":858,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":859,"interventions":860},[78],[15],[105,418,419,420],{"trials":862,"activeCount":85},[],{"intervention":450,"totalTrials":115,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":879},{"trials":866,"activeCount":85},[],{"trials":868,"activeCount":85},[],{"trials":870,"activeCount":85},[],{"trials":872,"activeCount":85},[],{"trials":874,"activeCount":85},[875],{"nctId":441,"briefTitle":442,"status":97,"phases":876,"primaryCompletion":444,"completion":445,"start":315,"enrollment":446,"conditions":877,"interventions":878},[78],[448],[428,450,451],{"trials":880,"activeCount":85},[],{"intervention":882,"totalTrials":115,"cells":883},"Sarcosine and SSRI",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":902},{"trials":885,"activeCount":85},[],{"trials":887,"activeCount":85},[],{"trials":889,"activeCount":85},[],{"trials":891,"activeCount":85},[],{"trials":893,"activeCount":85},[894],{"nctId":895,"briefTitle":896,"status":97,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":102,"conditions":900,"interventions":901},"NCT04975100","Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder",[78],"2023-04-30","2021-08-26",[21],[882],{"trials":903,"activeCount":85},[],{"intervention":461,"totalTrials":115,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":920},{"trials":907,"activeCount":85},[],{"trials":909,"activeCount":85},[],{"trials":911,"activeCount":85},[],{"trials":913,"activeCount":85},[],{"trials":915,"activeCount":85},[916],{"nctId":453,"briefTitle":454,"status":97,"phases":917,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":918,"interventions":919},[78],[23],[428,461,451],{"trials":921,"activeCount":85},[],{"intervention":923,"totalTrials":115,"cells":924},"Pregabalin 150mg",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":947},{"trials":926,"activeCount":85},[],{"trials":928,"activeCount":85},[],{"trials":930,"activeCount":85},[],{"trials":932,"activeCount":85},[],{"trials":934,"activeCount":85},[935],{"nctId":936,"briefTitle":937,"status":97,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT03604354","Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Surgery",[78],"2020-03-24","2020-05-19","2018-08-01",95,[944],"Osteoarthritis, Knee",[946,923],"Tapentadol 100 MG Oral",{"trials":948,"activeCount":85},[],{"intervention":950,"totalTrials":115,"cells":951},"Tazarotene 0.1% gel plus clindamycin 1% gel",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":972},{"trials":953,"activeCount":85},[],{"trials":955,"activeCount":85},[],{"trials":957,"activeCount":85},[],{"trials":959,"activeCount":85},[],{"trials":961,"activeCount":85},[962],{"nctId":963,"briefTitle":964,"status":97,"phases":965,"primaryCompletion":966,"completion":967,"start":515,"enrollment":102,"conditions":968,"interventions":970},"NCT02721173","Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris",[78],"2016-12","2017-01",[969],"Acne Vulgaris",[950,971],"Adapalene 0.1% gel plus clindamycin 1% gel",{"trials":973,"activeCount":85},[],{"intervention":971,"totalTrials":115,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":990},{"trials":977,"activeCount":85},[],{"trials":979,"activeCount":85},[],{"trials":981,"activeCount":85},[],{"trials":983,"activeCount":85},[],{"trials":985,"activeCount":85},[986],{"nctId":963,"briefTitle":964,"status":97,"phases":987,"primaryCompletion":966,"completion":967,"start":515,"enrollment":102,"conditions":988,"interventions":989},[78],[969],[950,971],{"trials":991,"activeCount":85},[],{"intervention":520,"totalTrials":115,"cells":993},{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1000,"PHASE4":1002,"NA":1008},{"trials":995,"activeCount":85},[],{"trials":997,"activeCount":85},[],{"trials":999,"activeCount":85},[],{"trials":1001,"activeCount":85},[],{"trials":1003,"activeCount":85},[1004],{"nctId":510,"briefTitle":511,"status":97,"phases":1005,"primaryCompletion":513,"completion":514,"start":515,"enrollment":516,"conditions":1006,"interventions":1007},[78],[518],[520,487],{"trials":1009,"activeCount":85},[],{"intervention":1011,"totalTrials":115,"cells":1012},"Olanzapine",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1034},{"trials":1014,"activeCount":85},[],{"trials":1016,"activeCount":85},[],{"trials":1018,"activeCount":85},[],{"trials":1020,"activeCount":85},[],{"trials":1022,"activeCount":85},[1023],{"nctId":1024,"briefTitle":1025,"status":97,"phases":1026,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1032},"NCT03304457","Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia",[78],"2018-03-12","2018-03-25","2017-08-25",100,[15],[1011,1033],"Lurasidone",{"trials":1035,"activeCount":85},[],{"intervention":1033,"totalTrials":115,"cells":1037},{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1044,"PHASE4":1046,"NA":1052},{"trials":1039,"activeCount":85},[],{"trials":1041,"activeCount":85},[],{"trials":1043,"activeCount":85},[],{"trials":1045,"activeCount":85},[],{"trials":1047,"activeCount":85},[1048],{"nctId":1024,"briefTitle":1025,"status":97,"phases":1049,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":1030,"conditions":1050,"interventions":1051},[78],[15],[1011,1033],{"trials":1053,"activeCount":85},[],{"intervention":1055,"totalTrials":115,"cells":1056},"Alphalipoic acid",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1075},{"trials":1058,"activeCount":85},[],{"trials":1060,"activeCount":85},[],{"trials":1062,"activeCount":85},[],{"trials":1064,"activeCount":85},[],{"trials":1066,"activeCount":85},[1067],{"nctId":1068,"briefTitle":1069,"status":97,"phases":1070,"primaryCompletion":802,"completion":1071,"start":1072,"enrollment":415,"conditions":1073,"interventions":1074},"NCT04475276","Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases",[78],"2024-01-01","2021-02-23",[29],[1055],{"trials":1076,"activeCount":85},[],{"intervention":1078,"totalTrials":115,"cells":1079},"Melatonin 3 mg",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1084,"PHASE3":1086,"PHASE4":1088,"NA":1101},{"trials":1081,"activeCount":85},[],{"trials":1083,"activeCount":85},[],{"trials":1085,"activeCount":85},[],{"trials":1087,"activeCount":85},[],{"trials":1089,"activeCount":85},[1090],{"nctId":1091,"briefTitle":1092,"status":97,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1100},"NCT03590197","Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy",[78],"2020-03-03","2020-04-12","2018-08-06",104,[1099],"Generalized Epilepsy",[1078],{"trials":1102,"activeCount":85},[],{"intervention":1104,"totalTrials":115,"cells":1105},"Metformin",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1126},{"trials":1107,"activeCount":85},[],{"trials":1109,"activeCount":85},[],{"trials":1111,"activeCount":85},[],{"trials":1113,"activeCount":85},[],{"trials":1115,"activeCount":85},[1116],{"nctId":1117,"briefTitle":1118,"status":97,"phases":1119,"primaryCompletion":1120,"completion":803,"start":1121,"enrollment":102,"conditions":1122,"interventions":1124},"NCT05663749","Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics",[78],"2023-07-30","2022-09-20",[1123,15],"Metabolic Syndrome",[1104,1125],"Topiramate",{"trials":1127,"activeCount":85},[],{"intervention":1125,"totalTrials":115,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1138,"NA":1144},{"trials":1131,"activeCount":85},[],{"trials":1133,"activeCount":85},[],{"trials":1135,"activeCount":85},[],{"trials":1137,"activeCount":85},[],{"trials":1139,"activeCount":85},[1140],{"nctId":1117,"briefTitle":1118,"status":97,"phases":1141,"primaryCompletion":1120,"completion":803,"start":1121,"enrollment":102,"conditions":1142,"interventions":1143},[78],[1123,15],[1104,1125],{"trials":1145,"activeCount":85},[],{"intervention":1147,"totalTrials":115,"cells":1148},"Polyethylene Glycol",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1170,"NA":1172},{"trials":1150,"activeCount":85},[],{"trials":1152,"activeCount":85},[],{"trials":1154,"activeCount":85},[],{"trials":1156,"activeCount":85},[1157],{"nctId":1158,"briefTitle":1159,"status":97,"phases":1160,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1168},"NCT05341180","Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial",[76,77],"2023-07-20","2023-07-22","2022-05-27",144,[1166,1167],"Anal Fissure","Constipation",[1147,1169],"Isabgol + Lactulose",{"trials":1171,"activeCount":85},[],{"trials":1173,"activeCount":85},[],{"intervention":1169,"totalTrials":115,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":85},[],{"trials":1179,"activeCount":85},[],{"trials":1181,"activeCount":85},[],{"trials":1183,"activeCount":85},[1184],{"nctId":1158,"briefTitle":1159,"status":97,"phases":1185,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1186,"interventions":1187},[76,77],[1166,1167],[1147,1169],{"trials":1189,"activeCount":85},[],{"trials":1191,"activeCount":85},[],{"intervention":1193,"totalTrials":115,"cells":1194},"Oral hypoglycemic agents [Metformin +\u002F- Sulfonylurea]",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1213,"NA":1215},{"trials":1196,"activeCount":85},[],{"trials":1198,"activeCount":85},[],{"trials":1200,"activeCount":85},[],{"trials":1202,"activeCount":85},[1203],{"nctId":1204,"briefTitle":1205,"status":97,"phases":1206,"primaryCompletion":1207,"completion":1208,"start":414,"enrollment":1209,"conditions":1210,"interventions":1212},"NCT02786823","Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes",[76,77],"2017-08-15","2017-09-15",80,[1211],"Diabetes Mellitus, Type 2",[1193],{"trials":1214,"activeCount":85},[],{"trials":1216,"activeCount":85},[],{"intervention":1218,"totalTrials":115,"cells":1219},"Tulsi(Ocimum sanctum Linn.)",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1221,"activeCount":85},[],{"trials":1223,"activeCount":85},[],{"trials":1225,"activeCount":85},[1226],{"nctId":1227,"briefTitle":1228,"status":97,"phases":1229,"primaryCompletion":515,"completion":515,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1234},"NCT02681939","Effect of Tulsi (Ocimum Sanctum) on Biochemical Parameters in Young Overweight and Obese Subjects",[76],"2016-02",30,[1233],"Obesity",[1218],{"trials":1236,"activeCount":85},[],{"trials":1238,"activeCount":85},[],{"trials":1240,"activeCount":85},[],{"intervention":1242,"totalTrials":9,"cells":1243},"Tapentadol 100 MG",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1252,"NA":1258},{"trials":1245,"activeCount":85},[],{"trials":1247,"activeCount":85},[],{"trials":1249,"activeCount":85},[],{"trials":1251,"activeCount":85},[],{"trials":1253,"activeCount":85},[1254],{"nctId":936,"briefTitle":937,"status":97,"phases":1255,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":1256,"interventions":1257},[78],[944],[946,923],{"trials":1259,"activeCount":85},[1260],{"nctId":1261,"briefTitle":1262,"status":97,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":516,"conditions":1267,"interventions":1269},"NCT03351517","Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty",[79],"2018-08-20","2018-09-07","2017-11-01",[1268],"Analgesia",[1242],{"intervention":1271,"totalTrials":115,"cells":1272},"Selenium",{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1274,"activeCount":85},[],{"trials":1276,"activeCount":85},[],{"trials":1278,"activeCount":85},[],{"trials":1280,"activeCount":85},[],{"trials":1282,"activeCount":85},[],{"trials":1284,"activeCount":85},[1285],{"nctId":1286,"briefTitle":1287,"status":650,"phases":1288,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1296},"NCT06413043","Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy",[79],"2025-08-05","2025-11-05","2024-05-06",78,[1294,1295],"Thyroid Eye Disease","Graves Ophthalmopathy",[1271],{"intervention":1298,"totalTrials":115,"cells":1299},"Risperidone, Aripiprazole",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1301,"activeCount":85},[],{"trials":1303,"activeCount":85},[],{"trials":1305,"activeCount":85},[],{"trials":1307,"activeCount":85},[],{"trials":1309,"activeCount":85},[],{"trials":1311,"activeCount":85},[1312],{"nctId":1313,"briefTitle":1314,"status":650,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1322},"NCT05868720","EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL",[79],"2024-05-02","2025-03-02","2023-07-01",42,[1321],"The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level",[1298],{"intervention":1324,"totalTrials":115,"cells":1325},"Levothyroxine",{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1327,"activeCount":85},[],{"trials":1329,"activeCount":85},[],{"trials":1331,"activeCount":85},[],{"trials":1333,"activeCount":85},[],{"trials":1335,"activeCount":85},[],{"trials":1337,"activeCount":85},[1338],{"nctId":1339,"briefTitle":1340,"status":97,"phases":1341,"primaryCompletion":1342,"completion":1343,"start":1344,"enrollment":415,"conditions":1345,"interventions":1346},"NCT02467244","Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism",[],"2018-09-30","2018-12-30","2017-02-01",[27],[1324],{"intervention":1348,"totalTrials":115,"cells":1349},"Enhanced Recovery after Surgery group",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1351,"activeCount":85},[],{"trials":1353,"activeCount":85},[],{"trials":1355,"activeCount":85},[],{"trials":1357,"activeCount":85},[],{"trials":1359,"activeCount":85},[],{"trials":1361,"activeCount":85},[1362],{"nctId":1363,"briefTitle":1364,"status":97,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":102,"conditions":1369,"interventions":1374},"NCT04194060","ERAS vs Conventional Approach in Peptic Perforation-RCT",[79],"2021-05-15","2021-06-15","2020-01-20",[1370,31,1371,1372,1373],"Peptic Ulcer Perforation","Post-Op Complication","Emergencies","Perioperative Complication",[1348,1375],"Conventional",{"intervention":1375,"totalTrials":115,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1379,"activeCount":85},[],{"trials":1381,"activeCount":85},[],{"trials":1383,"activeCount":85},[],{"trials":1385,"activeCount":85},[],{"trials":1387,"activeCount":85},[],{"trials":1389,"activeCount":85},[1390],{"nctId":1363,"briefTitle":1364,"status":97,"phases":1391,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":102,"conditions":1392,"interventions":1393},[79],[1370,31,1371,1372,1373],[1348,1375],{"intervention":1395,"totalTrials":115,"cells":1396},"Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1403,"PHASE4":1405,"NA":1407},{"trials":1398,"activeCount":85},[],{"trials":1400,"activeCount":85},[],{"trials":1402,"activeCount":85},[],{"trials":1404,"activeCount":85},[],{"trials":1406,"activeCount":85},[],{"trials":1408,"activeCount":85},[1409],{"nctId":1410,"briefTitle":1411,"status":97,"phases":1412,"primaryCompletion":1413,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1419},"NCT02693392","Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes",[79],"2018-04-30","2018-08-16","2016-01-17",200,[1418],"Type-2 Diabetes Mellitus",[1395],{"intervention":214,"totalTrials":115,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1423,"activeCount":85},[],{"trials":1425,"activeCount":85},[],{"trials":1427,"activeCount":85},[],{"trials":1429,"activeCount":85},[],{"trials":1431,"activeCount":85},[],{"trials":1433,"activeCount":85},[1434],{"nctId":204,"briefTitle":205,"status":97,"phases":1435,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":1436,"interventions":1437},[],[212],[214,200,52]]